Following the expiration of Empagliflozin's patent, the Indian pharmaceutical market has seen a surge, with 71 new brands and 17 companies introducing their versions. This influx has significantly increased sales, driven by prices that are 80-90% lower than the original. The increased affordability is expected to improve access for a wider population, with further market expansion anticipated.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/d9F3q8t
via IFTTT
Home »
Healthcare/Biotech-Industry-Economic Times
» As Empagliflozin goes off patent, 71 copies of the key diabetes drug roll out in a month
0 comments:
Post a Comment